At first glance, inflammation in general and growth 1.1 mesangioproliferative nephritis in rats [2] . A more factors in particular represent an extremely complex, if potent PDGF antagonist, a specific DNA-aptamer, was not chaotic, ensemble and clinicians are often confused also highly effective in reducing mesangial proliferation by an ever-growing list of factors and a wealth of data and matrix accumulation in this model [3] . More imporon their biological activities. Given the redundancy of tant, a few days of treatment with this latter antagonist many growth factor actions and the myriad of their muduring the mesangioproliferative phase of a chronic antitual interactions, it has come as somewhat of a surprise Thy 1.1 model completely prevented the subsequent dethat specific antagonism of single cytokines is not only velopment of renal failure and glomerular as well as possible but also highly effective in clinical situations.
tubulointerstitial scarring [4] . This study by Ostendorf The best example so far is the impressive effect of tumor et al thereby provided the first evidence of the long-held necrosis factor-␣ (TNF-␣) blockade in patients with belief that specific reduction of mesangial cell proliferarheumatoid arthritis or inflammatory bowel disease. tion in vivo is indeed a meaningful therapeutic approach Over the last years considerable evidence has been to mesangioproliferative disease [4] . gathered to implicate platelet-derived growth factor
The major disadvantages of the abc PDGF-B antago-(PDGF) in the pathogenesis of renal disease [reviewed nists are the need for parenteral application, the cost of in 1]. In the molecule, two chains, PDGF-A and PDGF-B, producing them, and, in the case of neutralizing antibodform the biologically active homo-or heterodimers (very ies, their immunogenicity. Given the slowly progressive recently, novel PDGF-C and PDGF-D chains have been nature of most human mesangioproliferative diseases, cloned but nothing is known on their renal actions). In prolonged treatment is usually necessary and would be the glomerulus, the PDGF-B chain, either as part of greatly facilitated if PDGF-B antagonists were easy to PDGF-BB or PDGF-AB, is the most active molecule.
produce and could be taken orally. Unfortunately, to PDGF-B is produced within the glomerulus, released date, only a few oral anti-PDGF agents are available. by infiltrating cells, overexpressed in many glomerular Trapidil, originally marketed as an antiplatelet agent, diseases, and in vitro potently increases proliferation and also inhibits the binding of PDGF to its receptor [5] matrix synthesis in mesangial cells. In vivo, administraand results in a moderate reduction of glomerular cell tion of PDGF-BB or the glomerular transfection with proliferation in the anti-Thy 1.1 nephritis model [6] .
PDGF-B cDNA results in mesangioproliferative changes
Whether this is the result of its antiplatelet or anti-PDGF without other renal pathology. The most convincing eviactivity presently remains unknown. More recently, tyrodence for a crucial and nonredundant role of PDGF-B sine kinase blockers have been developed, which more in mesangial biology is derived from mice genetically or less specifically impair the ability of the PDGF recepdeficient in PDGF-B or its receptor, which after birth tor to signal through its intracellular tyrosine kinase doquickly die of renal abnormalities. The notable abnormain. Again, using the anti-Thy 1.1 model, an inhibitor mality is in the glomeruli, which contain normal glomeru-(KI 6896) that can be taken orally and prevents autophoslar endothelial and epithelial cells and a normal basephorylation of both the PDGF receptor ␤-chain and the ment membrane, but completely lack a mesangium. basic fibroblast growth factor (bFGF) receptor, has been Given the above, antagonism of PDGF-B in glomerushown to reduce glomerular cell proliferation but not lar disease has become the focus of several studies. Exmatrix accumulation in vivo [7] . This study now has been periments with a neutralizing antibody against PDGF extended by Gilbert et al, who, in this issue of Kidney confirmed that it can acutely decrease mesangial cell
International [8] , report their experience with a tyrosine proliferation and matrix accumulation in the anti-Thy kinase inhibitor (STI 571, formerly referred to as Novartis compound CGP 57148) that blocks the PDGF receptor, the nonreceptor tyrosine kinase Abl, as well provide convincing evidence that STI 571, administered candidate for our future therapeutic repertoire to combat glomerular disease in humans. intraperitoneally from day 1 to 6 after induction of antiThy 1.1 nephritis, can lead to a highly significant reduc- In addition to its role in mesangioproliferative disease, Klinikum der RWTH, Pauwelsstr. 30, D-52074 Aachen, Germany. E-mail: Juergen.Floege@post.rwth-aachen.de 
